Navigation Links
BioLife Solutions Expands Strategic Relationship with STEMCELL Technologies Inc.
Date:8/13/2013

BOTHELL, Wash., Aug. 13, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced an expansion of its relationship with Vancouver, BC-based STEMCELL Technologies Inc. Since August 2009, STEMCELL Technologies has distributed BioLife's best in class biopreservation media products to the worldwide research and clinical biobanking communities. The previous news release can be found here: http://www.prnewswire.com/news-releases/biolife-solutions-and-stemcell-technologies-announce-worldwide-distribution-agreement-62233737.html

(Logo: http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO)

In an expansion of the relationship, STEMCELL Technologies recently selected BioLife's CryoStor cGMP freeze media for use in the launch of over 50 new primary cell products (from bone marrow, peripheral blood, umbilical cord blood, and umbilical cord tissue), to be marketed to the research community.

Mike Rice, BioLife Solutions President and CEO, commented on STEMCELL's product launch by stating, "We are quite pleased that STEMCELL Technologies has incorporated CryoStor into this new cell product portfolio. This is further validation of the superior preservation efficacy and overall value proposition of pre-formulated CryoStor when used with blood-derived cell types. We look to future growth in our business with STEMCELL Technologies and are glad to see our intellectual property enabling a revenue source for this strategic distributor."

A February 2013 report by visiongain predicts that the world market for cell-based assays will reach $4.7 billion in 2016.

David Llewellyn, Ph.D., MBA, Senior Director, Business Operations of STEMCELL Technologies commented on the expansion of the relationship with BioLife; "We have been very pleased with the performance of BioLife's products and the company's overall support. BioLife has become an increasingly strategic supplier of our research products. Our customers value the quality and performance of BioLife's biopreservation media products. Along with our own internal research, customer feedback gives us confidence to incorporate CryoStor into our new primary cell product portfolio."

About STEMCELL Technologies STEMCELL Technologies Inc. is a leader in the development of specialty cell culture media, cell isolation products and ancillary reagents for life science research.  Driven by science and a passion for quality, STEMCELL Technologies provides over 1500 products to more than 70 countries worldwide.  To learn more about how STEMCELL Technologies facilitates life science research, please visit http://www.stemcell.com/.

About BioLife SolutionsBioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions for cells, tissues, and organs.  The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death.  BioLife's enabling technology provides academic and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs.  BioLife Solutions is certified to ISO13485:2003. For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact.  Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission.  BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.  Media & Investor RelationsDaphne TaylorSenior Vice President, Chief Financial Officer(425) 686-6002 dtaylor@biolifesolutions.com
'/>"/>

SOURCE BioLife Solutions, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BioLife Solutions Announces Record Revenue of $2.3 Million in the Second Quarter of 2013
2. BioLife Solutions Announces Strategic Partnership with HemaCare
3. BioLife Solutions Named One of Washingtons Best Companies
4. BioLife Solutions Announces Record Revenue of $2.2 Million in First Quarter of 2013
5. BioLife Solutions Announces License Agreement
6. BioLife Solutions Announces 2012 Third Quarter Results: Ninth Straight Quarter of Record Revenue
7. BioLife Solutions Announces Presentation at IBC Inaugural Cell Therapy Clinical Development Conference
8. BioLife Solutions Announces 2012 Second Quarter Results: Eighth Straight Quarter of Record Revenue
9. BioLife Solutions Completes Corporate Facilities Expansion, Build-Out of Additional cGMP Clean Room Manufacturing Suite
10. Improved Cord Blood Processing Research on BioLife Solutions CryoStor® Published in TRANSFUSION
11. BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... N.J. (PRWEB) , ... September ... ... have recently published findings of a study examining the effects of exoskeleton-assisted ... with spinal cord injury (SCI). The article, "Neuromechanical adaptations during a robotic ...
(Date:9/20/2017)... Palo Alto, CA (PRWEB) , ... September 20, ... ... and public interest organization focused on molecular manufacturing and other transformative technologies, announced ... categories, one for Experiment and the other for Theory in nanotechnology/molecular manufacturing. , ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... automates the most dangerous step of sample prep for metals digestion—the addition of ... automation at an affordable price. The system is ideal for any laboratory performing ...
(Date:9/19/2017)... ... September 19, 2017 , ... A ... funded early-stage tech companies. “Grit” author Angela Duckworth and her team at Character ... community is Cooley, an international law firm with decades of experience supporting high-growth ...
Breaking Biology Technology:
(Date:5/6/2017)... -- RAM Group , Singaporean based technology ... biometric authentication based on a novel  quantum-state ... perform biometric authentication. These new sensors are based on a ... Group and its partners. This sensor will have widespread ... security. Ram Group is a next generation sensor ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
Breaking Biology News(10 mins):